<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-two patients with either a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> were treated with 10-21 days of subcutaneous <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) (5-10 mg/m2 every 12 hours) </plain></SENT>
<SENT sid="1" pm="."><plain>There were two complete remissions and ten partial responses </plain></SENT>
<SENT sid="2" pm="."><plain>Clinically significant improvements in peripheral blood counts persisted for periods of 8 weeks to greater than 21 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Responses were seen even in patients who had previously proven refractory to conventional induction regimens or high-dose Ara-C </plain></SENT>
<SENT sid="4" pm="."><plain>The toxicity, however, was considerable </plain></SENT>
<SENT sid="5" pm="."><plain>Nearly <z:hpo ids='HP_0000001'>all</z:hpo> patients developed significant <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Platelet and red cell transfusion support was required in many cases </plain></SENT>
<SENT sid="7" pm="."><plain>The response to low-dose Ara-C therapy seen in patients with the leukemic and <z:mpath ids='MPATH_341'>myelodysplastic disorders</z:mpath> may be mediated by the induction of cell differentiation or a direct cytotoxic effect on a sensitive population of cells </plain></SENT>
<SENT sid="8" pm="."><plain>Low-dose Ara-C may provide an alternative therapy in the selected patient with <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> or a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>